Новые панкреатические гормоны: амилин (обзор литературы)

1.    Амилин, или островковый амилоидный полипептид / [Электронный ресурс]. — Режим доступа: URL: http://www.medkarta.com/?cat=article&id=26216 (дата обращения: 03.10.2014).
2.    Амилин и сократительная активность лимфатических микрососудов брыжейки / С.В. Герман, Ф.И. Комаров, Г.Дж.С. Купер [и др.] // Рос. журн. гастроэнтерол., гепатол., колопроктол. — 1999. — Т. 9, № 5. — С. 56—60.
3.    Воздействие панкреатического полипептида амилина на язвообразование и на кислую желудочную секрецию / С.В. Герман, Г.Дж. Купер, Г.Н. Копылова [и др.] // Вестн. РАМН. — 1998. — № 4. — С. 10—12.
4.    Герман С.В. Панкреатический гормон амилин (Обзор литературы) // Рос. журн. гастроэнтерол., гепатол., колопроктол. — 2000. — Т. 10, № 6. — С. 14—21.
5.    Лукьянцева Г.В. Участие панкреатического гормона амилина в поддержании гомеостаза слизистой оболочки желудка: дис. д-ра биол. наук. — М., 2002. — 132 с.
6.    Панкреатический гормон амилин и целостность слизистой оболочки желудка / С.В. Герман, С.Е. Жуйкова, Ф.И. Комаров [и др.] // Вестн. РАМН. — 2001. — № 12. — С. 34—38.
7.    Acute effects of the human amylin analog AC137 on basal and insulin stimulated euglycemic and hypoglycemic fuel metabolism in patients with insulin-dependent diabetes mellitus / B. Nyholm, N. Moller, C.H. Gravholt [et al.] // J. CliN. Endocrinol. Metab. — 1996. — V. 81. — P. 1083—1089.
8.    A novel peptide in the caloitonin gene related peptide family as an amyloid fibril protein the endocrine pancreas / P. Westermark, C. Wernstedt, E. Wilcnder
[et al.] // Biochem. Biophys. Res. CommuN. — 1986. — V. 140. —
Р. 827—831.
9.    Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogene metabolism in skeletal muscle / G.F.S. Cooper, B. Leighton, G.D. Dimitriadis [et al.] // Proc. Natl. Acad.Sci. USA. — 1988. — V. 85, N. 20. — P. 7763—7766.
10.    Amylin given by central and peripheral routes inhibits acid gastric secretion / F. Guidobono, M. Coluzzi, F. Pagani [et al.] // Peptides. — 1994. — V. 15, N. 4. — P. 699—702.
11.    Amylin given by central or peripheral routes decreases gastric emptying and intestinal transit in the rat / G. Clementi, A. Caruso, V.M. Cutuli [et al.] // Experientia. — 1996. — V. 52, N. 7. — P. 677—679.
12.    Amylin: history and overview / B. Ludvic, A. Kautzky-Willer, R. Prager [et al.] // Diabet Med. — 1997. — V. 14. — P. S9—S13.
13.    Amylin immunoreactivity in the rat trachea and characterization of the interaction of amylin and somatostatin on airway mucus secretion / U. Wagner, D. Bredenbruker, P.J. Barth [et al.] // Res. Exp. Med. (Berl.). — 1995. — V. 195, N. 5. — P. 289—296.
14.    Amylin-induced in vivo insulin resistance in conscious rats: the liver is more sensitive to amylin than peripheral tissues / S.J. Koopmans, A.D. van Mansfeld, H.S. Yansz [et al.] // Diabetologia. — 1991. — V. 34, N. 4. — P. 218—224.
15.    Amylin inhibits bone resorption by a direct effect on the motility of rat osteoclasts / A.S. Alam, B.S. Moonga, P.J. Вevis [et al.] // Exp. Physiol. — 1993. — V. 78, N. 2. — P. 183—196.
16.    Amylin is a growth factor during fetal and postnatal development of the rat kidney / P.J. Wookey, C. Tikellis, M. Nobes [et al.] // Kidney Int. — 1998. — V. 53, N. 1. — P. 25—30.
17.    Amylin secretion from the rat pancreas and its selective loss after streptozotocin treatment / A. Ogawa, V. Harris, S.K. Ne Corkle [et al.] // J. CliN. Invest. — 1990. — V. 85. — P. 973—976.
18.    Amylin stimulates osteoblast proliferation and increases mineralized bone volume in adult mice / J. Cornish, K.E. Callon, G.J. Cooper [et al.] // Biochem. Biophys. Res. CommuN. — 1995. — V. 207, N. 1. — Р. 133—139.
19.    Amylin stimulates proximal tubular sodium transport and cell proliferation in the rat kidney / P.J. Harris, M.E. Cooper, S. Hiranyachattada [et al.] // Amer. J. Physiol. — 1997. — V. 272, N. 1, pt 2. — P. F13—F21.
20.    Amylin stimulates the renin-angiotensin-aldosterone axis in rats and man / A.A. Young, A. Nuttall, C. Moyses [et al.] // Diabetologia. — 1995. — V. 38, Suppl.1. — P. 225— 225.
21.    Basal and stimulated plasma levels of pancreatic amylin indicate its cosecretion with insulin in humans / E. Hartter, T. Svoboda, B. Ludvik [et al.] // Diabetologia. — 1991. — V. 34. — P. 52—54.
22.    Castillo M.J., Scheen A.J., Lefibvre P.J. Amylin/islet amyloid polypeptide: biochemistry, physiology, patho-physiology // Diabete Metab. — 1995. — V. 21, N. 1. — P. 3—25.
23.    Characterization of binding sites for amylin, calcitonin, and CGRP in primate kidney / S.Y. Chai, G. Christopoulos, M.E. Cooper [et al.] // Amer. J. Physiol. — 1998. — V. 274, N. 1, pt 2. — P. F51— F62.
24.    Cooper G.J.S. Amylin compared with calcitonin gene-related peptide: structure, biology, and relevance to metabolic disease // Endocrinol. ReV. — 1994. — V. 15, N. 2. — P. 163—201.
25.    Cooper G.J.S. Therapeutic potential of human amylin analoges in diabetes mellitus // Bio-Drugs. — 1998. — V. 10, N. 1. — P. 1—9.
26.    Coordinate regulation of amylin and insulin expression in response to hypoglycemia and fasting / T. Alam, L. Chen, A. Ogawa [et al.] // Diabetes. — 1992. — V. 41, N. 4. — P. 508—514.
27.    Deems R.O., Deacon R.W., Young D.A. Amylin activates glycogen phosphorylase and inactivates glycogen synthase via a cAMP-independent mechanism // Biochem. Biophys. Res. CommuN. — 1991. — V. 174. — P. 716—720.
28.    Effects of adrenomedullin, calcitonin gene-related peptide, and amylin on cerebral circulation in dogs / M.K. Baskaya, Y. Suzuki, M. Anzai [et al.] // J. Cereb. Blood Flow Metab. — 1995. — V. 15, N. 5. — P. 827—834.
29.    Effects of amylin on appetite regulation and memory / J.E. Morley, J.F. Flood, S.A. Farr [et al.] // CaN. J. Physiol. Pharmacol. — 1995. — V. 73. — P. 1042—1046.
30.    Effects of amylin on human osteoblast-like cells / I. Villa, A. Rubinacci, F. Ravasi [et al.] // Peptides. — 1997. — V. 18, N. 4. — Р. 537—540.
31.    Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans / P.C. Butler, C. Chou, W.B. Carter [et al.] // Diabetes. — 1990. — V. 39. — P. 752—756.
32.    Evidence of cosecretion of islet amyloid polypeptide and insulin by β-cells / S.E. Kahn, D.A. D’Alessio, M.W. Schwartz [et al.] // Diabetes. — 1990. — V. 39. — P. 634—638.
33.    Fatty acids induce amylin expression and secretion by pancreatic beta-cells / D. Qi, K. Cai, O. Wang [et al.] // Am. J. Physiol. Endocrinol. Metab. — 2010. — V. 298, N. 1. — P. E99—E107.
34.    Flood J.F., Morby J.E. Differential effects of amylin on memory processing using peripheral and central routes of administration // Peptides. — 1992. — V. 13. — P. 577—580.
35.    Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin / A.A. Young, B. Gedulin, W. Vine [et al.] // Diabetologia. — 1995. — V. 38. — P. 642—648.
36.    Gedulin B.R., Rink T.J., Young A.A. Dose response for glucagonostatic effect of amylin in rats // Metabolism. — 1997. — V. 46, N. 1. — P. 67—70.
37.    Gulli G., Rossetti L., DeFronzo R.A. Hyperamylinemia is associated with hyperinsulinemia in the glucose-tolerant, insulin-resistant offspring of two Mexican-American non-insulindependent diabetic parents // Metabolism. — 1997. — V. 46, N. 10. — P. 1157—1161.
38.    Haynes J.M., Hodgson W.C., Cooper M.E. Rat amylin mediates a pressor response in the anaesthetized rat: implications for the association between hypertension and diabetes mellitus // Diabetologia. — 1997. — V. 40, N. 3. — P. 256—261.
39.    High affinity amylin binding sites in rat brain / K. Beaumont, M.A. Kenney, A.A. Young [et al.] // Mol. Pharmacol. — 1993. — V. 44. — P. 493—497.
40.    Hinciar J. Amylin as an additional possible pathogenic factor in NIDDM and the insulin resistance syndrome // Vnitr. Lek. — 1996. — V. 42, N. 8. — P. 557—560.
41.    Höppener J.W., Ahrén B., Lips C.J. Islet amyloid and type 2 diabetes mellitus // N. Engl. J. Med. — 2000. — V. 343, N. 6. — P. 411—419.
42.    IAPP/amylin transgenic mice as an in vivo model system for type-2 diabetes mellitus / J.W. Höppener, C. Oosterwijk, S.J. Verbeek [et al.] // Biochem. Soc. Trans. — 1993. — V. 21. — P. 28S.
43.    IAPP and insulin kinetics and insulin sensitivity in gestational diabetes mellitus / A. Kautzky-Willer, G. Pacini, K. Thomaseth [et al.] // Diabetologia. — 1995. — V. 38. — P. A282.
44.    Identification and characterization of islet amyloid polypeptide in mammalian gastrointestinal tract / M. Miyazato, M. Nakazato, K. Shiomi [et al.] // Biochem. Biophys. Res. CommuN. — 1991. — V. 181. — P. 293—300.
45.    Immunoreactivity and expression of amylin in astroenteropancreatic endocrine tumors / R. Eissele, C. Neuhaus, M.E. Trautmann [et al.] // Amer. J. Pathol. — 1993. — V. 143, N. 1. — Р. 283—291.
46.    Insulin resistance caused by amylin in conscious rats is independent of induced hypocalcemia and fades during long-term exposure / C. Furnsinn, P. Nowotny, M. Roden [et al.] // Acta Endocr. (Kbh). — 1993. — V. 129, N. 4. —
P. 360—365.
47.    Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes / R.L. Hull, G.T. Westermark, P. Westermark [et al.] // J. CliN. Endocrinol. Metab. — 2004. — V. 89. — P. 3629—3643.
48.    Islet amyloid polypeptide (IAPP) in the gastrointestinal tract and pancreas of man and rat / H. Toshimori, R. Narita, M. Nakazato [et al.] // Cell. Tissue Res. — 1990. — V. 262. — P. 401—406.
49.    Islet amyloid polypeptide-producing pancreatic islet cell tumor. A clinical and biochemical characterization / M. Stridsberg, E. Wilander, K. Oberg [et al.] // Scand. J. Gastroenterol. — 1992. — V. 27. — P. 381—387.
50.    Islet amyloid polypeptide response to glucose, insulin, and somatostatin analogue administration / T. Mitsukawa, J. Takemura, J. Asai [et al.] // Diabetes. — 1990. — V. 39. — P. 639—641.
51.    In vitro autoradiographic localization of amylin binding sites in rat brain / P.M. Sexton, G. Paxinos, M.A. Kenney [et al.] // Neuroscience. — 1994. — V. 62, N. 2. — P. 553—567.
52.    Jodka C., Green D., Young A. Amylin modulation of gastric emptying in rats depends upon an intact vagus nerve // Diabetes. — 1996. — 45, Suppl. 2. — P. S235—S235.
53.    Johnson K.H., O’Brien T.D., Westermark P. Newly identified pancreatic protein islet amyloid polypeptide. What is its relationship to diabetes? // Diabetes. — 1991. — V. 40, N. 3. — P. 310—314.
54.    Lack of acute effect of amylin (islet associated polypeptide) on insulin sensitivity during hyperinsulinaemic euglycaemic clamp in humans / J.P. Wilding, N. Khandan-Nia, W.M. Bennet [et al.] // Diabetologia. — 1994 — V. 37, N. 2. — P. 166—169.
55.    Leighton B., Foot E. The effects of amylin on carbohydrate metabolism in skeletal muscle in vitro and in vivo // Biochem. J. — 1990. — V. 269. — P. 19—22.
56.    Lutz T.A., Del Prete E., Scharrer E. Reduction of food intake in rats by intraperitoneal injection of low doses of amylin // Physiol. BehaV. — 1994. — V. 55. — P. 891—895.
57.    Lutz T.A., Del Prete E., Scharrer E. Subdiaphragmatic vagotomy does not influence the anorectic effect of amylin // Peptides. — 1995. — V. 16. — P. 457—462.
58.    Macdonald I.A. Amylin and the gastrointestinal tract // Diabet. Med. — 1997. — V. 14, Suppl. 2. — P. S24—S28.
59.    Molecular and functional characterization of amylin, a peptide associated with type 2 diabetes mellitus / A.N. Roberts, B. Leighton, J.A.Todd [et al.] // Proc. Natl. Acad. Sci. U.S.A. — 1989. — V. 86, N. 24. — P. 9662—9666.
60.    Molecular physiology of amylin / R.A. Pittner, K. Albrandt, K. Beaumont [et al.] // J. Cell. Biochem. — 1994. — V. 55. — P. 19—28.
61.    Morley J.E., Flood J.F. Amylin decreases food intake in mice // Peptides. — 1991. — V. 12. — P.865—869.
62.    O'Brien Т.D. [et al.]. — 1995. — ЦиТ. по 1.
63.    Opie E.L. On the relation of chronic interstitial pancreatitis to the islands of Langerhans and to diabetes mellitus // J. Exp. Med. — 1901. — V. 5. — P. 397—428.
64.    Permeability of the blood-brain barrier to amylin / W.A. Banks, A.J. Kastin, L.M. Maness [et al.] // Life Sci. — 1995. — V. 57, N. 22. — P. 1993—2001.
65.    Plasma islet amyloid polypeptide (amylin) levels and their responses to oral glucose in Tipe 2 (non-insulindependent) diabetic patients / T. Sanke, T. Hanabusa, Y. Nakano [et al.] // Diabetologia. — 1991. — V. 34. — 129—132.
66.    Potency and effectiveness of amylin and five gut peptides on gastric emptying in rats / B.R. Gedulin, C.M. Jodka, D.E. Green [et al.] // Diabetes. — 1995. — V. 44, Suppl. — P. 133A.
67.    Protection by amylin of gastric erosions induced by indomethacin or ethanol in rats / F. Guidobono, F. Pagani, C. Ticozzi [et al.] // Brit. J. Pharmacol. — 1997. — V. 120, N. 4. — P. 581—586.
68.    Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients / G.J.S. Cooper, A.S. Willis, A. Clark [et al.] // Proc. Nath. Acad. Sci. USA — 1987. — V. 84. — P. 8628—8632.
69.    Rat amylin- (8—37) enchances insulin action and alters lipid metabolism in normal and insulin resistant rats / M. Hettiarachchi, S. Chalkley, A. Watkinson [et al.] // Amer. J. Physiol. — 1997. — V. 273. — P. 859—867.
70.    Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analog / O. Kolterman, A.B. Gottlieb, C. Moyses [et al.] // Diabetes Care. — 1995. — V. 18. — P. 1179—1182.
71.    Relative hypersecretion of amylin to insulin from rat pancreas after neonatal STZ treatment / K. Inoue, A. Hisatomi, F. Umeda [et al.] // Diabetes. — 1992. — V. 41, N. 6. — P. 723—727.
72.    Rogers R.C., McTigue D.M., Hermann G.E. Vagal control of digestion: modulation by central neural and peripheral endocrine factors // Neurosci. BiobehaV. ReV. — 1996. — V. 20. — P. 57—66.
73.    Schmitz O., Brock B., Rungby J. Amylin agonists: a novel approach in the treatment of diabetes // Diabetes. — 2004. — V. 53, Suppl 3. — P. S233—S238.
74.    Silvestre R.A. [et al.]. — 1997. — ЦиТ. по 1.
75.    TNF-α acutely upregulates amylin expression in murine pancreatic beta cells / K. Cai, D. Qi, O. Wang [et al.] // Diabetologia. — 2011. — V. 54, N. 3. — P. 617—626.
76.    Very high concentrations of islet amyloid polypeptide are necessary to alter the insulin response to intravenous glucose in man / D. Bretherton-Watt, S.G. Gilbey, M.A. Ghatei [et al.] // J. CliN. Endocrinol. Metabol. — 1992. — V. 74, N. 5. — P. 1032—1035.
77.    Weichselbaum A., Stangl E. Zur Kenntnis der feineren Veranderungen des Pankreas bei Diabetes Mellitus // WieN. kliN. Wschr. — 1901. — B. 14. — S. 968—972.
78.    Wimalawama S.J., Gunasakera R.D., Datta H.K. Hypocalcemic actions of amylin amide in humans // J. Bone Miner. Res. — 1992. — V. 7, N. 9. — P. 1113—1116.
79.    Young A., Denaro M. Roles of amylin in diabetes and in regulation of nutrient load // NutritioN. — 1998. — V. 14, N. 6. — P. 524—527.
80.    Zaki М. [et al.]. — 1996. — ЦиТ. по 1.

1. Aniline or islet amyloid polypeptide. Available at: http://www.medkarta.com/?cat=article&id=26216 (accessed: 03 October 2014).
2. German S.V., Komarov F.I., Kuper G.Dzh.S. Aniline and contractile activity of lymphatic microvessel mesentery. Ros. zhurn. gastroenterol., gepatol., koloproktol. [Russian journal of gastroenterology, hepatology, coloproctology], 1999, vol. 9, no. 5, pp. 56—60 (In Russian).
3. German S.V., Kuper G.Dzh., Kopylova G.N. Exposure of pancreatic polypeptide amylin on ulceration and gastric acid secretion. Vestn. RAMN. [Newsletter of Medical Sciences], 1998, no. 4, pp. 10—12 (In Russian).
4. German S.V. Pancreatic hormone aniline (Literature Review). Ros. zhurn. gastroenterol., gepatol., koloproktol. [Russian journal of gastroenterology, hepatology, coloproctology], 2000, vol. 10, no. 6, pp. 14—21 (In Russian).
5. Luk'iantseva G.V. The participation of the pancreatic hormone amylin homeostasis in the gastric mucosa. Dr. boil. sci. diss. Moscow, 2002. 132 p. (In Russian).
6. German S.V., Zhuikova S.E., Komarov F.I. Pancreatic hormone aniline and integrity of the gastric mucosa. Vestn. RAMN. [Newsletter of Medical Sciences], 2001, no. 12, pp. 34—38 (In Russian).
7. Nyholm B., Moller N., Gravholt C.H. Acute effects of the human amylin analog AC137 on basal and insulin stimulated euglycemic and hypoglycemic fuel metabolism in patients with insulin-dependent diabetes mellitus. J. CliN. Endocrinol. Metab, 1996, vol. 81, pp. 1083—1089.
8. Westermark P., Wernstedt C., Wilcnder E. A novel peptide in the caloitonin gene related peptide family as an amyloid fibril protein the endocrine pancreas. Biochem. Biophys. Res. CommuN., 1986, vol. 140, pp. 827—831.
9. Cooper G.F.S., Leighton B., Dimitriadis G.D. Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogene metabolism in skeletal muscle. Proc. Natl. Acad.Sci. USA, 1988, vol. 85, no. 20, pp. 7763—7766.
10. F. Guidobono, M. Coluzzi, F. Pagani. Amylin given by central and peripheral routes inhibits acid gastric secretion. Peptides, 1994, vol. 15, no. 4, pp. 699—702.
11. Clementi G., Caruso A., Cutuli V.M. Amylin given by central or peripheral routes decreases gastric emptying and intestinal transit in the rat. Experientia, 1996, vol. 52, no. 7, pp. 677—679.
12. Ludvic B., Kautzky-Willer A., Prager R. Amylin: history and overview. Diabet Med., 1997, vol. 14, pp. S9—S13.
13. Wagner U., Bredenbruker D., Barth P.J. Amylin immunoreactivity in the rat trachea and characterization of the interaction of amylin and somatostatin on airway mucus secretion. Res. Exp. Med. (Berl.), 1995, vol. 195, no. 5, pp. 289—296.
14. S.J. Koopmans, A.D. van Mansfeld, H.S. Yansz. Amylin-induced in vivo insulin resistance in conscious rats: the liver is more sensitive to amylin than peripheral tissues. Diabetologia, 1991, vol. 34, no. 4, pp. 218—224.
15. Alam A.S., Moonga B.S., Вevis P.J. Amylin inhibits bone resorption by a direct effect on the motility of rat osteoclasts. Exp. Physiol., 1993, vol. 78, no. 2, pp. 183—196.
16. Wookey P.J., Tikellis C., Nobes M. Amylin is a growth factor during fetal and postnatal development of the rat kidney. Kidney Int., 1998, vol. 53, no. 1, pp. 25—30.
17. Ogawa A., Harris V., Ne Corkle S.K. Amylin secretion from the rat pancreas and its selective loss after streptozotocin treatment. J. CliN. Invest., 1990, vol. 85, pp. 973—976.
18. Cornish J., Callon K.E., Cooper G.J. Amylin stimulates osteoblast proliferation and increases mineralized bone volume in adult mice. Biochem. Biophys. Res. CommuN, 1995, vol. 207, no. 1, pp. 133—139.
19. Harris P.J., Cooper M.E., Hiranyachattada S. Amylin stimulates proximal tubular sodium transport and cell proliferation in the rat kidney. Amer. J. Physiol., 1997, vol. 272, no. 1, pt 2, pp. F13—F21.
20. Young A.A., Nuttall A., Moyses C. Amylin stimulates the renin-angiotensin-aldosterone axis in rats and man. Diabetologia, 1995, vol. 38, suppl.1, pp. 225— 225.
21. Hartter E., Svoboda T., Ludvik B. Basal and stimulated plasma levels of pancreatic amylin indicate its cosecretion with insulin in humans. Diabetologia, 1991, vol. 34, pp. 52—54.
22. Castillo M.J., Scheen A.J., Lefibvre P.J. Amylin/islet amyloid polypeptide: biochemistry, physiology, patho-physiology. Diabete Metab., 1995, vol. 21, no. 1, pp. 3—25.
23. Chai S.Y., Christopoulos G., Cooper M.E. Characterization of binding sites for amylin, calcitonin, and CGRP in primate kidney. Amer. J. Physiol., 1998, vol. 274, no. 1, pt 2, pp. F51— F62.
24. Cooper G.J.S. Amylin compared with calcitonin gene-related peptide: structure, biology, and relevance to metabolic disease. Endocrinol. ReV., 1994, vol. 15, no. 2, pp. 163—201.
25. Cooper G.J.S. Therapeutic potential of human amylin analoges in diabetes mellitus. Bio-Drugs, 1998, vol. 10, no. 1, pp. 1—9.
26. Alam T., Chen L., Ogawa A. Coordinate regulation of amylin and insulin expression in response to hypoglycemia and fasting. Diabetes, 1992, vol. 41, no. 4, pp. 508—514.
27. Deems R.O., Deacon R.W., Young D.A. Amylin activates glycogen phosphorylase and inactivates glycogen synthase via a cAMP-independent mechanism. Biochem. Biophys. Res. CommuN., 1991, vol. 174, pp. 716—720.
28. Baskaya M.K., Suzuki Y., Anzai M. Effects of adrenomedullin, calcitonin gene-related peptide, and amylin on cerebral circulation in dogs. J. Cereb. Blood Flow Metab., 1995, vol. 15, no. 5, pp. 827—834.
29. Morley J.E., Flood J.F., Farr S.A. Effects of amylin on appetite regulation and memory. CaN. J. Physiol. Pharmacol., 1995, vol. 73, pp. 1042—1046.
30. Villa I., Rubinacci A., Ravasi F. Effects of amylin on human osteoblast-like cells. Peptides, 1997, vol. 18, no. 4, pp. 537—540.
31. Butler P.C., Chou C., Carter W.B. Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. Diabetes., 1990, vol. 39, pp. 752—756.
32. Kahn S.E., D’Alessio D.A., Schwartz M.W. Evidence of cosecretion of islet amyloid polypeptide and insulin by β-cells. Diabetes, 1990, vol. 39,
pp. 634—638.
33. Cai D. Qi, K., Wang O. Fatty acids induce amylin expression and secretion by pancreatic beta-cells. Am. J. Physiol. Endocrinol. Metab., 2010, vol. 298, no. 1, pp. E99—E107.
34. Flood J.F., Morby J.E. Differential effects of amylin on memory processing using peripheral and central routes of administration. Peptides, 1992, vol. 13, pp. 577—580.
35. Young A.A., Gedulin B., Vine W. Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia, 1995, vol. 38, pp. 642—648.
36. Gedulin B.R., Rink T.J., Young A.A. Dose response for glucagonostatic effect of amylin in rats. Metabolism, 1997, vol. 46, no. 1, pp. 67—70.
37. Gulli G., Rossetti L., DeFronzo R.A. Hyperamylinemia is associated with hyperinsulinemia in the glucose-tolerant, insulin-resistant offspring of two Mexican-American non-insulindependent diabetic parents. Metabolism, 1997, vol. 46, no. 10, pp. 1157—1161.
38. Haynes J.M., Hodgson W.C., Cooper M.E. Rat amylin mediates a pressor response in the anaesthetized rat: implications for the association between hypertension and diabetes mellitus. Diabetologia. 1997, vol. 40, no. 3, pp. 256—261.
39. Beaumont K., Kenney M.A., Young A.A. High affinity amylin binding sites in rat brain. Mol. Pharmacol., 1993, vol. 44, pp. 493—497.
40. Hinciar J. Amylin as an additional possible pathogenic factor in NIDDM and the insulin resistance syndrome. Vnitr. Lek., 1996, vol. 42, no. 8, pp. 557—560.
41. Höppener J.W., Ahrén B., Lips C.J. Islet amyloid and type 2 diabetes mellitus. N. Engl. J. Med., 2000, vol. 343, no. 6, pp. 411—419.
42. Höppener J.W., Oosterwijk C., Verbeek S.J. IAPP/amylin transgenic mice as an in vivo model system for type-2 diabetes mellitus. Biochem. Soc. Trans., 1993, vol. 21, pp. 28S.
43. Kautzky-Willer A., Pacini G., Thomaseth K. IAPP and insulin kinetics and insulin sensitivity in gestational diabetes mellitus. Diabetologia, 1995, vol. 38, pp. A282.
44. Identification and characterization of islet amyloid polypeptide in mammalian gastrointestinal tract. Biochem. Biophys. Res. CommuN. 1991, vol. 181, pp. 293—300.
45. Eissele R., Neuhaus C., Trautmann M.E. Immunoreactivity and expression of amylin in astroenteropancreatic endocrine tumors. Amer. J. Pathol., 1993, vol. 143, no. 1, pp. 283—291.
46. Furnsinn C., Nowotny P., Roden M. Insulin resistance caused by amylin in conscious rats is independent of induced hypocalcemia and fades during long-term exposure. Acta Endocr. (Kbh), 1993, vol. 129, no. 4, pp. 360—365.
47. Hull R.L., Westermark G.T., Westermark P. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J. CliN. Endocrinol. Metab., 2004, vol. 89, pp. 3629—3643.
48. Toshimori H., Narita R., Nakazato M. Islet amyloid polypeptide (IAPP) in the gastrointestinal tract and pancreas of man and rat. Cell. Tissue Res., 1990, vol. 262, pp. 401—406.
49. Stridsberg M., Wilander E., Oberg K. Islet amyloid polypeptide-producing pancreatic islet cell tumor. A clinical and biochemical characterization. Scand. J. Gastroenterol, 1992, vol. 27, pp. 381—387.
50. Mitsukawa T., Takemura J., Asai J. Islet amyloid polypeptide response to glucose, insulin, and somatostatin analogue administration. Diabetes, 1990, vol. 39, pp. 639—641.
51. Sexton P.M. , Paxinos G., Kenney M.A. In vitro autoradiographic localization of amylin binding sites in rat brain. Neuroscience, 1994, vol. 62, no. 2, pp. 553—567.
52. Jodka C., Green D., Young A. Amylin modulation of gastric emptying in rats depends upon an intact vagus nerve. Diabetes, 1996, 45, suppl. 2, pp. S235—S235.
53. Johnson K.H., O’Brien T.D., Westermark P. Newly identified pancreatic protein islet amyloid polypeptide. What is its relationship to diabetes? Diabetes, 1991, vol. 40, no. 3, pp. 310—314.
54. Wilding J.P., Khandan-Nia N., Bennet W.M. Lack of acute effect of amylin (islet associated polypeptide) on insulin sensitivity during hyperinsulinaemic euglycaemic clamp in humans. Diabetologia, 1994, vol. 37, no. 2, pp. 166—169.
55. Leighton B., Foot E. The effects of amylin on carbohydrate metabolism in skeletal muscle in vitro and in vivo. Biochem. J., 1990, vol. 269, pp. 19—22.
56. Lutz T.A., Del Prete E., Scharrer E. Reduction of food intake in rats by intraperitoneal injection of low doses of amylin. Physiol. BehaV., 1994, vol. 55, pp. 891—895.
57. Lutz T.A., Del Prete E., Scharrer E. Subdiaphragmatic vagotomy does not influence the anorectic effect of amylin. Peptides, 1995, vol. 16, pp. 457—462.
58. Macdonald I.A. Amylin and the gastrointestinal tract. Diabet. Med., 1997, vol. 14, suppl. 2, pp. S24—S28.
59. Roberts A.N., Leighton B., Todd J.A. Molecular and functional characterization of amylin, a peptide associated with type 2 diabetes mellitus. Proc. Natl. Acad. Sci. U.S.A, 1989, vol. 86, no. 24, pp. 9662—9666.
60. Pittner R.A., Albrandt K., Beaumont K. Molecular physiology of amylin. J. Cell. Biochem, 1994, vol. 55, pp. 19—28.
61. Morley J.E., Flood J.F. Amylin decreases food intake in mice. Peptides., 1991, vol. 12, pp.865—869.
62. O'Brien Т.D. 1995., ЦиТ. по 1.
63. Opie E.L. On the relation of chronic interstitial pancreatitis to the islands of Langerhans and to diabetes mellitus. J. Exp. Med., 1901, vol. 5, pp. 397—428.
64. Banks W.A., Kastin A.J., Maness L.M. Permeability of the blood-brain barrier to amylin. Life Sci., 1995, vol. 57, no. 22, pp. 1993—2001.
65. Sanke T., Hanabusa T., Nakano Y. Plasma islet amyloid polypeptide (amylin) levels and their responses to oral glucose in Tipe 2 (non-insulindependent) diabetic patients. Diabetologia, 1991, vol. 34, pp.129—132.
66. Gedulin B.R., Jodka C.M., Green D.E. Potency and effectiveness of amylin and five gut peptides on gastric emptying in rats. Diabetes, 1995, vol. 44, suppl., p. 133A.
67. Guidobono F., Pagani F., Ticozzi C. Protection by amylin of gastric erosions induced by indomethacin or ethanol in rats. Brit. J. Pharmacol., 1997, vol. 120, no. 4, pp. 581—586.
68. Cooper G.J.S., Willis A.S., Clark A. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients / [et al.] // Proc. Nath. Acad. Sci. USA — 1987. — V. 84. — P. 8628—8632.
69. Hettiarachchi M., Chalkley S., Watkinson A. Rat amylin- (8—37) enchances insulin action and alters lipid metabolism in normal and insulin resistant rats. Amer. J. Physiol., 1997, vol. 273, pp. 859—867.
70. Kolterman O., Gottlieb A.B., Moyses C. Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analog. Diabetes Care, 1995, vol. 18, pp. 1179—1182.
71. Inoue K., Hisatomi A., Umeda F. Relative hypersecretion of amylin to insulin from rat pancreas after neonatal STZ treatment. Diabetes, 1992, vol. 41, no. 6, pp. 723—727.
72. Rogers R.C., McTigue D.M., Hermann G.E. Vagal control of digestion: modulation by central neural and peripheral endocrine factors. Neurosci. BiobehaV. ReV., 1996, vol. 20, pp. 57—66.
73. Schmitz O., Brock B., Rungby J. Amylin agonists: a novel approach in the treatment of diabetes. Diabetes., 2004, vol. 53, suppl 3, pp. S233—S238.
74. Silvestre R.A. 1997, ЦиТ. по 1.
75. Cai K., Qi D., Wang O. TNF-α acutely upregulates amylin expression in murine pancreatic beta cells. Diabetologia, 2011, vol. 54, no. 3, pp. 617—626.
76. Bretherton-Watt D., Gilbey S.G., Ghatei M.A. Very high concentrations of islet amyloid polypeptide are necessary to alter the insulin response to intravenous glucose in man. J. CliN. Endocrinol. Metabol., 1992, vol. 74, no. 5, pp. 1032—1035.
77. Weichselbaum A., Stangl E. Zur Kenntnis der feineren Veranderungen des Pankreas bei Diabetes Mellitus. WieN. kliN. Wschr., 1901, b. 14, pp. 968—972.
78. Wimalawama S.J., Gunasakera R.D., Datta H.K. Hypocalcemic actions of amylin amide in humans. J. Bone Miner. Res., 1992, vol. 7, no. 9, pp. 1113—1116.
79. Young A., Denaro M. Roles of amylin in diabetes and in regulation of nutrient load. NutritioN, 1998, vol. 14, no. 6, pp. 524—527.
80. Zaki М. 1996, ЦиТ. по 1.